Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Want to see AU:NSB full AI Analyst Report?
Top Page
Neuroscientific Biopharmaceuticals Ltd.
(Sydney:NSB)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.06
▼(-37.00% Downside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial performance (volatile/collapsed revenue and recurring losses with ongoing cash burn) and a bearish technical setup (price below all key moving averages with negative momentum). A debt-free balance sheet provides some resilience, but valuation is hard to justify with negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces solvency risk and eliminates interest expense, giving management structural flexibility to direct limited cash toward R&D, licensing or milestone spend. Over 2–6 months this supports resilience to funding volatility and improves partnerability.
Negative Factors
Revenue collapse and volatility
A move to zero annual revenue removes internal funding for operations and indicates weak commercial traction. Over the next several months this heightens reliance on external funding or partnerships, increases execution risk for trials, and undermines sustainable product commercialization prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces solvency risk and eliminates interest expense, giving management structural flexibility to direct limited cash toward R&D, licensing or milestone spend. Over 2–6 months this supports resilience to funding volatility and improves partnerability.
Read all positive factors
Neuroscientific Biopharmaceuticals Ltd. (NSB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.94M
Dividend YieldN/A
Average Volume (3M)306.60K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue GrowthN/A
EPS Growth-285.37%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding389,718,540
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical...
How the Company Makes Money
null...
Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
67
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.21M | 4.95M | 0.00 | 958.77K |
| Gross Profit | -92.78K | -91.34K | -57.85K | -64.92K | 897.36K |
| EBITDA | -1.92M | -1.80M | -5.96M | -10.37M | -3.12M |
| Net Income | -1.85M | 324.21K | -1.07M | -10.44M | -3.18M |
Balance Sheet | |||||
| Total Assets | 16.96M | 5.44M | 5.29M | 7.74M | 14.83M |
| Cash, Cash Equivalents and Short-Term Investments | 7.27M | 4.95M | 4.91M | 7.22M | 14.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 149.22K | 85.68K | 597.36K | 2.22M | 223.41K |
| Stockholders Equity | 16.81M | 5.35M | 4.69M | 5.52M | 14.60M |
Cash Flow | |||||
| Free Cash Flow | -941.33K | 42.43K | -2.30M | -6.95M | -2.63M |
| Operating Cash Flow | -941.33K | 44.25K | -2.30M | -6.94M | -2.60M |
| Investing Cash Flow | -36.04K | -1.81K | 0.00 | -3.87K | -29.88K |
| Financing Cash Flow | 3.29M | 0.00 | 0.00 | 0.00 | 13.51M |
Neuroscientific Biopharmaceuticals Ltd. Technical Analysis
Negative
0.10
Price Trends
0.09
Negative
0.10
Negative
0.12
Negative
Market Momentum
>-0.01
Positive
27.70
Positive
-15.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.09, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.70 is Positive, neither overbought nor oversold. The STOCH value of -15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NSB.
Neuroscientific Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$109.49M | -12.05 | -100.58% | ― | ― | -9.57% | |
48 Neutral | AU$84.75M | -86.67 | -142.30% | ― | -45.25% | 40.54% | |
47 Neutral | AU$292.55M | -90.26 | -15.96% | ― | 364.97% | 74.50% | |
46 Neutral | AU$64.14M | -6.04 | -62.49% | ― | ― | -13.64% | |
42 Neutral | AU$24.94M | -4.21 | -19.10% | ― | ― | -285.37% | |
41 Neutral | AU$2.92M | -0.33 | -179.37% | ― | ― | 24.59% |
* Healthcare Sector Average
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.03
-28.89%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.14
-92.00%
AU:PTX
Prescient Therapeutics Limited
0.06
0.02
38.64%
AU:SPL
Starpharma Holdings Limited
0.70
0.61
689.77%
AU:ILA
Island Pharmaceuticals Ltd
0.37
0.23
164.29%
AU:ADO
AnteoTech Ltd
0.03
0.01
100.00%
Neuroscientific Biopharmaceuticals Ltd. Corporate Events
NeuroScientific Extends Insider Escrow as Major Share Block Set for Release
Jun 19, 2026
NeuroScientific Biopharmaceuticals has disclosed that 85,714,264 fully paid ordinary shares will come out of voluntary escrow on 27 June 2026, increasing the pool of tradable securities on the market. This scheduled escrow release could improve sh...
NeuroScientific Director Converts Performance Shares After SAS Milestone
Jun 2, 2026
NeuroScientific Biopharmaceuticals has disclosed a change in director Robert Leslie McKenzie’s indirect interest, following the conversion of performance shares into ordinary shares. Through Kilkenny Nominees Pty Ltd, McKenzie exchanged 3,85...
NeuroScientific Issues New ASX Securities Under Disclosure Exemption
Jun 1, 2026
NeuroScientific Biopharmaceuticals has issued quoted securities on the ASX without a prospectus, relying on a disclosure exemption under Section 708A(5) of the Corporations Act. The company confirmed it is fully compliant with its financial report...
Neuroscientific Biopharmaceuticals Seeks ASX Quotation for 57 Million New Shares
Jun 1, 2026
Neuroscientific Biopharmaceuticals Ltd., an ASX-listed biopharmaceutical company focused on neuroscientific therapies, has ordinary fully paid shares on issue under the ticker NSB. The company leverages the Australian capital market to support its...
NeuroScientific Biopharmaceuticals outlines stem cell strategy for severe Crohn’s disease
May 26, 2026
NeuroScientific Biopharmaceuticals has released an investor presentation outlining its strategy to develop a next-generation stem cell solution for patients with severe Crohn’s disease. The document is framed as high-level, non-advisory info...
NeuroScientific Seeks Trading Halt Ahead of Material Program Results
May 24, 2026
NeuroScientific Biopharmaceuticals Ltd. has requested a trading halt in its securities on the ASX, pending the release of results from a special access program it describes as material to the company. Trading in NSB shares is expected to resume on...
NeuroScientific advances StemSmart cell therapy with strong early Crohn’s data and scale-up plans
Apr 30, 2026
NeuroScientific Biopharmaceuticals reported a strong March quarter as it advanced its StemSmart™ cell therapy program for fistulising Crohn’s disease. The company is targeting difficult-to-treat inflammatory indications and is position...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.